Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 4, pp 305–315 | Cite as

Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent

  • Jeffrey G. Supko
  • Robert L. Hickman
  • Michael R. Grever
  • Louis Malspeis
Original Article Ansamycins, Antineoplasti Agents, Pharmacokinetic


The plasma pharmacokinetics of the antitumor antibiotic geldanamycin (GM; NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 μg/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro, were achieved in the plasma of the mice and the dog treated by i.v. injection. However, the systemic duration of the drug was relatively short. Plasma levels decayed below 0.1 μg/ml within 3–4 h after administration of the apparent maximum tolerated doses, which were approximately 20 mg/kg for the mice and 4 mg/kg for the dog. The drug exhibited linear pharmacokinetic behavior within the dose ranges studied. However, there were significant interspecies differences in its disposition. Whereas the mean biological half-life of GM was slightly longer in the mice (77.7 min) than in the dog (57.9 min), its mean residence time in the dog (46.6 min) was more than twofold greater than that observed in the mice (20.7 min). Nevertheless, the drug was cleared from plasma much faster by the dog (49.4 ml/min per kg) than by the mice (30.5 ml/min per kg). These apparent anomalies were principally associated with differences in the relative significance of the terminal phase upon overall drug disposition. The liver appeared to be the principal target organ of acute drug toxicity in the dog. Doses of 2.0 and 4.2 mg/kg both produced elevations in serum levels of the transaminases and other indicators of liver function characteristic of acute hepatic necrosis. Additional effects included symptoms of minor gastrointestinal toxicity and alterations in serum chemistry parameters consistent with less severe nephrotoxicity. Drug-related toxicity appeared to be reversible. In consideration of the potential for acute hepatotoxic reactions to GM, as well as to the other benzoquinoid ansamycins based upon structural analogy, additional pharmacological and therapeutic information is required to ascertain whether these compounds are viable candidates for clinical development.

Key words

Ansamycins Antineoplastic agents Pharmacokinetics 





internal standard


drug concentration for 50% inhibition of cell growth in vitro


drug concentration resulting in 50% lethality in cultured cells


National Cancer Institute


area under plasma concentrationtime curve between time zero and infinity


total plasma clearance


mean residence time


biological half-life


central compartment apparent volume of distribution


apparent volume of distribution at steady state


total body apparent volume of distribution


creatine phosphokinase


lactic dehydrogenase


serum oxaloacetic transaminase


serum glutamic-pyruvic transaminase


dimethyl sulfoxide


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benet LZ (1972) General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 61: 536Google Scholar
  2. 2.
    Boyd MR (1989) Status of the NCI preclinical antitumor drug discovery screen. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology updates, vol 3, number 10. Lippincott, Philadelphia, pp 1–12Google Scholar
  3. 3.
    De Boer C, Meulman PA, Wnuk RJ, Peterson,DH (1970) Geldanamycin, a new antibiotic. J Antibiot 23: 442Google Scholar
  4. 4.
    Frank LA (1990) Clinical pharmacology of rifampin. J Am Vet Med Assoc 197: 114Google Scholar
  5. 5.
    Fukazawa H, Li PM, Yamamoto C, Murakami Y, Mizuno S, Uehara Y (1991) Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem Pharmacol 42: 1661Google Scholar
  6. 6.
    Garcia R, Prikh NU, Saya H, Gallick GE (1991) Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines. Oncogene 6: 1983Google Scholar
  7. 7.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn, Marcel Dekker, New York, p 409Google Scholar
  8. 8.
    Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19: 662Google Scholar
  9. 9.
    Grosset J, Leventis S (1983) Adverse effects of rifampin. Rev Infect Dis 5: 5440Google Scholar
  10. 10.
    Hamaguchi M, Xiao H, Uehara Y, Ohnishi Y, Nagai Y (1993) Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3′ kinase. Oncogene 8: 559Google Scholar
  11. 11.
    Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S (1989) Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 49: 331Google Scholar
  12. 12.
    Honma Y, Kaskukabe T, Hozumi M, Shibata K, Omura S (1992) Effects of herbimycin A derivatives on growth and differentiation of K562 leukemic cells. Anticancer Res 12: 189Google Scholar
  13. 13.
    Honma Y, Okabe-Kado J, Kasukabe T, Hozumi M, Kodama H, Kajigaya S, Sda T, Miura Y (1992) Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression ofv-abl tyrosine kinase. Cancer Res 52: 4017Google Scholar
  14. 14.
    Insel PA (1990) Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The basis of therapeutics, 8th edn, Pergamon Press, New York, pp 657–658Google Scholar
  15. 15.
    Iwai Y, Nakagawa A, Sadakane N, Omura S, Oiwa H, Matsumoto S, Takahashi M (1980) Herbimycin B, a new benzoquinoid ansamycin with anti-TMV and herbicidal activities. J Antibiot 33: 1114Google Scholar
  16. 16.
    Li LH, Clark TD, Cowie CH, Rinehart KL Jr (1977) Effect of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of rauscher leukemia virus. Cancer Treat Rep 61: 815Google Scholar
  17. 17.
    Lin LZ, Blasko G, Cordell GA (1988)1H-NMR analysis of herbimycins and dihydro-herbimycins. J Nat Prod 51: 1161Google Scholar
  18. 18.
    Miner DJ, Kissinger PT (1979) Evidence for the involvement ofN-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem Pharmacol 28: 3285Google Scholar
  19. 19.
    Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB (1973) Acetaminophen-induced hepatic necrosis. IV. Role of drug metabolism. J Pharmacol Exp Ther 187: 185Google Scholar
  20. 20.
    Muroi M, Izawa M, Kosai Y, Asai M (1980) Macbecins I and II, new antitumor antibiotics II. Isolation and characterization. J Antibiot 33: 205Google Scholar
  21. 21.
    Muroi M, Haibara K, Asai M, Kamiya K, Kishi T (1981) The structures of macbecin I and II Tetrahedron 37: 1123Google Scholar
  22. 22.
    Omura H, Hasegawa Y, Ikai T (1979) Herbimycin, a new antibiotic produced by a strain ofStreptomyces. J Antibiot 32: 255Google Scholar
  23. 23.
    Omura S, Miyano K, Nakagawa A, Sano H, Komiyama K, Umezawa I (1984) Chemical modification and antitumor activity of herbimycin A. 8,9-Epoxide, 7,9-cyclic carbamate, and 17 or 19-amino derivatives. J Antibiot 37: 1264Google Scholar
  24. 24.
    Ono Y, Kozai Y, Ootsu K (1982) Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. Gann 73: 938Google Scholar
  25. 25.
    Peehl DM (1992) Culture of human prostatic epithelial cells. In: Freshney IA (ed) Culture of epithelial cells, Wiley Liss, New York, pp 159–180Google Scholar
  26. 26.
    Peehl D, Erickson E, Malspeis L, Orr J, Mayo J, Camalier R, Monks A, Cronise P, Paull K, Grever MR (1993) Prostate cancer: NCI drug discovery efforts (abstract). Proc Am Assoc Cancer Res 34: 369Google Scholar
  27. 27.
    Rinehart KL Jr, Shield LS (1976) Chemistry of the ansamycin antibiotics. Fortschr Chem Org Naturst 33: 231Google Scholar
  28. 28.
    Rosenkrantz H, Hadidian Z, Seay H, Mason MM (1963) Dimethyl sulfoxide: its steroid solubility and endocrinologic and pharmacologic-toxicologic characteristics. Cancer Chemother Rep 31: 7Google Scholar
  29. 29.
    Rowland M, Tucker G (1980) Symbols in pharmacokinetics. J Pharmacokinet Biopharm 8: 497Google Scholar
  30. 30.
    Sano H, Komiyama K, Nakagawa A, Omura S (1986) Chemical modification of herbimycin A. Synthesis andin vivo antitumor activities of halogenated and other related derivatives of herbimycin A. J Antibiot 39: 415Google Scholar
  31. 31.
    Sasaki K, Rinehart KL Jr, Slomp G, Grostic MF, Olson EC (1970) Geldanamycin. I. Structure assignment. J Am Chem Soc 92: 7591Google Scholar
  32. 32.
    Sasaki K, Yasuda H, Onodera K (1979) Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot 32: 849Google Scholar
  33. 33.
    Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6: 2198Google Scholar
  34. 34.
    Uehara Y, Murakami Y, Sugimoto Y, Mizuno S (1989) Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1. Cancer Res 49: 780Google Scholar
  35. 35.
    Uehara Y, Fukazawa H, Murakami Y, Mizuno S (1989) Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 163: 803Google Scholar
  36. 36.
    Whitesell L, Shifrin SD, Schwab G, Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated tosrc kinase inhibition. Cancer Res 52: 1721Google Scholar
  37. 37.
    Willson JE, Brown DE, Timmens EK (1965) A toxicological study of dimethyl sulfoxide. Toxicol Appl Pharmacol 7: 104Google Scholar
  38. 38.
    Wintrobe MM, Thorn GW, Adams RD, Braunwald E, Isselbacher KJ, Petersdorf RG (eds.) (1972) Principles of internal medicine, 7th edn, McGraw-Hill, New York, pp 1200–1202, 1513–1519, 1912Google Scholar
  39. 39.
    Yamaki H, Suzuki H, Choi EC, Tanaka N (1982) Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group. J Antibiot 35: 886Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Jeffrey G. Supko
    • 1
  • Robert L. Hickman
    • 2
  • Michael R. Grever
    • 1
  • Louis Malspeis
    • 1
  1. 1.Laboratory of Pharmaceutical Chemistry, Developmental Therapeutics Program, Division of Cancer TreatmentNational Cancer InstituteFrederickUSA
  2. 2.Pathology Associates, Inc.FrederickUSA

Personalised recommendations